Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 6/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | GPER1 | Q99527 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26024965 | 0.89 | NR1I2 (0.36) | CASP3BACE1BRD4DRD2DRD3 | |
| SCHEMBL26750458 | 0.81 | PDE5A (0.44) | BRD4ALDH1A1GAA | |
| SCHEMBL26621463 | 0.80 | ATAD2 (0.50) | BRD4DRD2DRD3ALDH1A1GAA | |
| SCHEMBL27071712 | 0.80 | BRD4 (0.38) | BRD4DRD2DRD3ALDH1A1GAA | |
| SCHEMBL26021777 | 0.80 | CRHR1 (0.44) | BRD4DRD2ALDH1A1GAA | |
| SCHEMBL26021802 | 0.80 | BMPR1B (0.46) | CASP3BACE1BRD4DRD2DRD3 | |
| SCHEMBL31419462 | 0.80 | ATAD2 (0.50) | BRD4DRD2DRD3ALDH1A1GAA | |
| SCHEMBL17979389 | 0.78 | ATAD2 (0.43) | CASP3DRD2DRD3PNMT | |
| SCHEMBL26021793 | 0.77 | BMPR1B (0.45) | CASP3BRD4DRD2DRD3HTR7 | |
| SCHEMBL25899787 | 0.76 | BMPR1B (0.48) | CASP3BACE1BRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | CASP3 2129/4885BACE1 35/4885BRD4 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.